Key points are not available for this paper at this time.
Nefecon is a novel, oral, targeted-release capsule formulation of budesonide, designed to treat immunoglobulin A nephropathy (IgAN) by inhibiting IgA formation in the Peyer's patch–rich distal ileum. Based on Phase 3 interim results, the US Food and Drug Administration and European Medicines Agency approved the use of Nefecon in patients with primary IgAN. Data collected over a 9-month period from the initial 199 patients with IgAN in the Phase 3 Efficacy and Safety of Nefecon in Patients With Primary IgA Nephropathy (NefIgArd) trial showed a significant reduction in urine protein–creatinine ratio (UPCR) and preservation of the estimated glomerular filtration rate (eGFR) with Nefecon versus placebo (Barratt J, et al.
Lafayette et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: